Image 1
Desvenlafaxine Tablet, Extended Release
Product Images NDC 0591-4060
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 0591-4060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image 2
This appears to be a statistical analysis table that shows ratios and confidence intervals for different conditions and populations. It includes information on renal and hepatic impairment, as well as gender and age as factors affecting drug metabolism. However, without context or additional information it is unclear what specific drug, study or disease is being analyzed.*
Image 3
This appears to be a table or chart related to changes in CYP3A4 inhibitors and their effect on Ketoconazole Cmax (maximum concentration). The table displays geometric mean ratios (with 90% confidence intervals) for two different changes relative to a reference. More context is needed to understand the significance of these changes.*
Image 4
Image 5
This appears to be a graph showing the estimated proportion of patients who experienced relapse over time. The x-axis represents the time to relapse in days from randomization, while the y-axis shows the estimated percentage of patients experiencing relapse. The graph compares Desvenlafaxine Extended-Release Tablets 50 mg to a placebo treatment.*
Image 6
This is a graph that shows the estimated proportion of patients with relapse over time, in days from randomization. The graph compares the results for Desvenlafaxine Extended-Release Tablets with those for a placebo. The percentages range from 0% to 8%.*
Image 7
This is a medication guide for Desvenlafaxine Extended-Release Tablets, which consist of 30 film-coated tablets containing 38mg desvenlafaxine succinate (25mg desvenlafaxine equivalent). The guide instructs pharmacists to dispense it with the medication and advises patients to swallow the tablets whole and not to cut, chew, or dissolve them. The recommended dosage is specified in the accompanying prescribing information. The medication should be stored at 20°C to 25°C, with excursions permitted between 15°C to 30°C, and the product is intended to be dispensed as a unit. The packaging lists Teva Pharmaceuticals as the manufacturer and cautions users to keep the medication out of the reach of children.*
Image 8
Desvenlafaxine is a medication used to treat depression. It is available in extended-release tablets, each containing 50mg of Desvenlafaxine. The tablets should be stored at a temperature between 20°C and 30°C. Pharmacists are advised to dispense the package intended to be dispensed as a unit and patients should swallow the tablet whole; not cut, crush, or chew it. This medication and all drugs should be kept out of the reach of children. The manufacturer is Tera Pharmaceuticals and this information is valid for the RevA32022 235168-02 version of the product.*
Image 9
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
